These data were not on the radar screen cause at that time sofosbuvir/RBV produced 100% SVR in GT2/3 in the ELECTRON trial. Now we will see what GILD are planing to do about GT3. You were correct before assuming GILD will look for an in-house solution, so I thought they might try GS-5885 instead of daclatasvir.
Unlike cancer, a modest improvement over existing SOC might not be good enough for approval in GT3. Especially when a more potent combo is being tested at the same point in time in GT1.
I think that even noninferiority to SOC is enough for approval in GT3 since GILD's combo treatment is shorter and better tolerated plus these patients have no other option.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.